Last reviewed · How we verify
Diclofenac Cream 8%
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of topical application.
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of topical application. Used for Topical treatment of localized pain and inflammation associated with osteoarthritis and other musculoskeletal conditions, Acute pain relief from minor sprains, strains, and contusions.
At a glance
| Generic name | Diclofenac Cream 8% |
|---|---|
| Sponsor | FPR Specialty Pharmacy |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | COX-1, COX-2 |
| Modality | Small molecule |
| Therapeutic area | Pain Management, Rheumatology |
| Phase | Phase 3 |
Mechanism of action
Diclofenac cream penetrates the skin to reach underlying tissues where it blocks COX-1 and COX-2 enzymes, reducing the production of inflammatory prostaglandins. This localized anti-inflammatory and analgesic effect provides pain relief and reduces swelling without the systemic exposure associated with oral NSAIDs. The 8% formulation delivers a higher concentration of the active ingredient to the affected area.
Approved indications
- Topical treatment of localized pain and inflammation associated with osteoarthritis and other musculoskeletal conditions
- Acute pain relief from minor sprains, strains, and contusions
Common side effects
- Local skin irritation or rash at application site
- Photosensitivity
- Pruritus
- Erythema
Key clinical trials
- Topical Arnica and Mucopolysaccharide Polysulfate on Postoperative Pain, Edema and Trismus (PHASE4)
- Treatment of Knee Pain With Topical Diclofenac Cream 8% or Diclofenac Gel 1% (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diclofenac Cream 8% CI brief — competitive landscape report
- Diclofenac Cream 8% updates RSS · CI watch RSS
- FPR Specialty Pharmacy portfolio CI